A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Psoriasis
Interventions
DRUG

BI 765250

BI 765250

DRUG

Placebo

placebo

Trial Locations (5)

1404

MBAL Sveta Sofia, Sofia

400347

Emergency County Hospital, Arensia EM, Cluj-Napoca

0112

ARENSIA Exploratory Medicine LLC, Tbilisi

MD-2025

"Clinical Republican Hospital Timofei Mosneaga", Chisinau

011658

MONZA Medical Center, Bucharest

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY